SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-298052
Filing Date
2022-12-05
Accepted
2022-12-05 08:41:05
Documents
17
Period of Report
2022-12-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d418804d8k.htm   iXBRL 8-K 44161
2 EX-4.1 d418804dex41.htm EX-4.1 87666
3 EX-10.1 d418804dex101.htm EX-10.1 160189
4 EX-10.2 d418804dex102.htm EX-10.2 152939
5 EX-99.1 d418804dex991.htm EX-99.1 14548
9 GRAPHIC g418804img001.jpg GRAPHIC 11563
  Complete submission text file 0001193125-22-298052.txt   703834

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA kpti-20221205.xsd EX-101.SCH 2847
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20221205_lab.xml EX-101.LAB 17994
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20221205_pre.xml EX-101.PRE 11259
11 EXTRACTED XBRL INSTANCE DOCUMENT d418804d8k_htm.xml XML 3342
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 221443841
SIC: 2834 Pharmaceutical Preparations